2,065.32 5.91 (-0.29%)

    678.60 7.75 (+1.16%)
  • Dollar/Won

    1,133.60 0.30 (+0.03%)
증권시황 정보 열기

SillaJen teams up with ABL Europe for development of oncolytic therapy JX-970

2018.01.22 15:14:02 | 2018.01.22 15:14:24
  • print
  • email
  • facebook
  • twitter
  • share
South Korea’s biopharmaceutical company SillaJen Inc. has signed a contract with ABL Europe, a French contract manufacturing organization (CMO), for production of its virus-based cancer treatment JX-970, the company announced on Monday.

Under the deal, ABL Europe will be responsible for producing JX-970 and managing its quality for SillaJen that plans to conduct clinical tests for the cancer-fighting immunotherapy in the first half of next year.

JX-970, derived from vaccinia vaccine strain, is designed to remove tumors selectively by inactivating thymidine kinase (TK) and vaccinia growth factor (VGF) gene, and express granulocyte macrophage colony-stimulating factor (GM-CSF) to stimulate immune responses. SillaJen is authorized for its global sales.

ABL Europe, based in Strasbourg in France, is also in charge of producing SillaJen’s investigational liver cancer treatment Pexa-Vec (JX-594) under a phase 3 clinical study.

As of 3:12 p.m. on Monday, shares of Kosdaq-listed SillaJen fell 0.68 percent to 102,300 won in Seoul trading.

By Shin Chan-ok and Choi Mira

[ⓒ Pulse by Maeil Business News Korea & mk.co.kr, All rights reserved]



  • Seoul Wed 14 November 2018
  • WED


Get Newsletters